Valiant Laboratories Limited — Others, 13-08-2025: Copy of Newspaper Publication

Valiant Laboratories has finalized the allotment for its Rights Issue, issuing 1.08 crore fully paid-up equity shares. These shares were priced at ₹75 each, including a premium of ₹65. The Rights Issue, totaling approximately ₹81.47 Cr, saw a strong oversubscription of 132.96%. This capital infusion will strengthen the company's financials. The new shares are expected to begin trading on the exchange around August 13, enhancing liquidity for shareholders who participated. This successful issue boosts Valiant's financial standing and future growth prospects.